Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$153.49 USD

153.49
4,164,591

+3.73 (2.49%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

HRMY or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. ILMN: Which Stock Is the Better Value Option?

Seeking Clues to Illumina (ILMN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results

by Zacks Equity Research

Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSPH

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Illumina (ILMN) Extends Partnership to Advance Cancer Test

by Zacks Equity Research

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Here's Why You Should Retain Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.

Illumina (ILMN) Expands Globally Despite Macroeconomic Woes

by Zacks Equity Research

The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.

Illumina (ILMN) Launches Initiative on Pathogen Sequencing

by Zacks Equity Research

Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.

LGND or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

Company News for Nov 13, 2023

by Zacks Equity Research

Companies In The News Are: ILMN, CTRE, WPM, FLO.

Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut

by Zacks Equity Research

Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.

Illumina (ILMN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Seeking Clues to Illumina (ILMN) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.

Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LGND vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.

LGND vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

NVIDIA and Illumina have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

NVIDIA and Illumina are part of the Zacks Bull and Bear of the Day article.

Kevin Cook headshot

Bear of the Day: Illumina (ILMN)

by Kevin Cook

Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares

Charles River (CRL) Launches LVV-based Gene Therapy Platform

by Zacks Equity Research

Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.

Guardant Health (GH) Surges 8.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Guardant Health (GH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up

by Zacks Equity Research

Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.

Illumina (ILMN) Down 14.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EXEL vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?